Oral ultra-low dose continuous combined hormone replacement therapy with 0.5mg 17β-oestradiol and 2.5mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study-Reference-Cited by-同舟云学术

Oral ultra-low dose continuous combined hormone replacement therapy with 0.5mg 17β-oestradiol and 2.5mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study

Published:2010-11 Issue:3 Volume:67 Page:227-232
ISSN:0378-5122
Container-title:Maturitas
language:en
Short-container-title:Maturitas

Author:

Stevenson John C.,Durand Gemma,Kahler Elke,Pertyński Tomasz

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,General Biochemistry, Genetics and Molecular Biology

Reference24 articles.

1. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review;Utian;Health Qual Life Outcomes,2005

2. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century;Rödström;Menopause,2002

3. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society;North American Menopause Society;Menopause,2004

4. Symptoms of menopause: hot flushes;Santoro;Clin Obstet Gynecol,2008

5. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society;North American Menopause Society;Menopause,2010

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormone Replacement Therapy (HRT) Shortages for Treating Menopause: What Can Clinicians Do to Relieve Symptoms and Concerns?;Sci;2024-08-02

2. Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and China;Climacteric;2024-07-30

3. Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis;Gynecological Endocrinology;2024-07-08

4. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause;Menopause;2023-11-27

5. Hormone therapy for sexual function in perimenopausal and postmenopausal women;Cochrane Database of Systematic Reviews;2023-08-24